Monden Y, Nakahara K, Iioka S, Nanjo S, Ohno K, Fujii Y, Hashimoto J, Kitagawa Y, Masaoka A, Kawashima Y
Ann Thorac Surg. 1985 Feb;39(2):165-9. doi: 10.1016/s0003-4975(10)62558-1.
Factors influencing the recurrence or persistence of thymoma after therapy were investigated in 127 patients with thymoma, including 75 with thymoma and myasthenia gravis. The rate of recurrence or persistence was 19% (24 of 127 patients) overall, 11% (8 of 75 patients) in myasthenic thymoma, and 31% (16 of 52 patients) in nonmyasthenic thymoma. The more advanced the clinical stage, the higher the rate of recurrence or persistence. The recurrence/persistence rate for patients with the same clinical stage was higher in those with nonmyasthenic thymoma (8% in Stage I, 11% in Stage II, 36% in Stage III, and 75% in Stage IV) than in those with myasthenic thymoma (0 in Stage I, 13% in Stage II, 18% in Stage III, and 20% in Stage IV). The prognosis for patients having subtotal resection of tumor was good in myasthenic thymoma (recurrence/persistence rate, 17%) in contrast with nonmyasthenic thymoma (recurrence/persistence rate, 78%). These results suggest that nonmyasthenic thymoma is more malignant than myasthenic thymoma. Postoperative radiotherapy was effective in preventing the recurrence or persistence of thymoma after therapy.
在127例胸腺瘤患者中研究了影响治疗后胸腺瘤复发或持续存在的因素，其中包括75例合并重症肌无力的胸腺瘤患者。总体复发或持续存在率为19%（127例患者中的24例），重症肌无力性胸腺瘤患者为11%（75例患者中的8例），非重症肌无力性胸腺瘤患者为31%（52例患者中的16例）。临床分期越晚，复发或持续存在率越高。相同临床分期的患者中，非重症肌无力性胸腺瘤患者的复发/持续存在率更高（I期为8%，II期为11%，III期为36%，IV期为75%），而重症肌无力性胸腺瘤患者的复发/持续存在率则较低（I期为0，II期为13%，III期为18%，IV期为20%）。与非重症肌无力性胸腺瘤（复发/持续存在率为78%）相比，重症肌无力性胸腺瘤患者行肿瘤次全切除后的预后较好（复发/持续存在率为17%）。这些结果表明，非重症肌无力性胸腺瘤比重症肌无力性胸腺瘤恶性程度更高。术后放疗对预防治疗后胸腺瘤的复发或持续存在有效。
